Henry James International Management Inc. Acquires New Position in MorphoSys AG (NASDAQ:MOR)

Henry James International Management Inc. bought a new stake in MorphoSys AG (NASDAQ:MOR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 43,000 shares of the company's stock, valued at approximately $426,000.

Separately, Optiver Holding B.V. raised its holdings in MorphoSys by 8,577.2% in the 3rd quarter. Optiver Holding B.V. now owns 144,042 shares of the company's stock valued at $968,000 after acquiring an additional 142,382 shares during the last quarter. 18.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MOR has been the topic of several recent research reports. Morgan Stanley restated an "equal weight" rating on shares of MorphoSys in a report on Friday, January 19th. Wells Fargo & Company reissued an "equal weight" rating and set a $18.25 price objective (up previously from $17.00) on shares of MorphoSys in a research note on Thursday, March 14th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $11.78.

MorphoSys Trading Up 0.1 %

NASDAQ:MOR traded up $0.02 on Friday, hitting $17.89. The stock had a trading volume of 458,755 shares, compared to its average volume of 619,250. The company has a fifty day moving average price of $17.95 and a two-hundred day moving average price of $12.59. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of -5.14 and a beta of 1.15. The company has a quick ratio of 2.84, a current ratio of 1.38 and a debt-to-equity ratio of 4.98. MorphoSys AG has a 1-year low of $4.18 and a 1-year high of $18.31.

MorphoSys (NASDAQ:MOR - Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The company reported $0.33 EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $1.25. The firm had revenue of $63.53 million for the quarter, compared to analysts' expectations of $76.30 million. MorphoSys had a negative return on equity of 10,108.30% and a negative net margin of 226.79%. Equities research analysts expect that MorphoSys AG will post -2.08 earnings per share for the current fiscal year.

MorphoSys Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.